Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Telo Genomics Corp V.TELO

Alternate Symbol(s):  TDSGF

Telo Genomics Corp. is a Canada-based biotech company. The Company is focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for diseases that display genomic instability. Its lead product, TeloView SMM, is a high-complexity molecular assay available for clinical use to provide information to physicians treating patients with Smoldering Multiple Myeloma. Through proprietary telomere-based analysis, TeloView SMM selects high-risk SMM patients who are likely to benefit from earlier treatment intervention while identifying the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment. The TeloView SMM assay has a potential total addressable market of over 500,000 tests per year.


TSXV:TELO - Post by User

Bullboard Posts
Comment by CMCents2investson Jul 20, 2017 4:49pm
88 Views
Post# 26492573

RE:from the short form prospectus

RE:from the short form prospectus
richandcorrupt wrote: from short form prospectus:

Hugh Rogers - never purchased even one share and is taking $8,000 each month for a part time job: Hugh Rogers VP Finance 403,760 shares at exercise price of $0.00025 exercised on January 5, 2016.

Name              Monthly Consulting Fee
John J. Swift $10,000 per month effective January 1, 2016
Ferenc Somogyvari $11,667 per month effective January 1, 2016
Keith B. Cassidy  $10,000 per month effective January 1, 2016
Hugh Rogers $8,000 per month effective January 1, 2016
Dr. Sabine Mai $2,000 per month effective September 1, 2015

Who could tell me what all these people do to "earn" this consulting fee?  Only people who should get paid a good consulting fee is Dr. Mai but she is the only one giving services at a discount and the rest are overpaid puppets draining the bank account.  


good post I agree shame

Bullboard Posts